Cargando…
A SEVERE ADVERSE DRUG REACTION (ADR) TO REGEN-COV (CASIRIVIMAB AND IMDEVIMAB)
INTRODUCTION: A promising means to limit the progression of the SARS-CoV-2 virus is the use of monoclonal antibodies (mAbs), which are able to recognize viral antigenic epitopes of the Spike protein. Despite their high degree of efficacy, mAbs are sometimes accompanied by adverse drug reactions (ADR...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646418/ http://dx.doi.org/10.1016/j.anai.2022.08.785 |